GET DAILY SIGNALSXencor (XNCR) Delivers Q3 2026 Profit on Collaboration Revenue Growth
Key Takeaways
- Third quarter 2026 revenue reached $116.5 million, up sharply from $21.0 million in the same period a year earlier.
- Net income came in at $39.4 million, or $0.50 per diluted share, versus a net loss of $6.0 million, or $(0.08) per share, in the prior-year quarter.
- Research and development (R&D) spending climbed to $84.3 million, while general and administrative (G&A) expenses fell to $9.4 million on a non-recurring legal expense recovery.
- The company reported $555.7 million in cash, cash equivalents, and marketable debt securities and expects to end 2026 with $480 million to $500 million.
- Results handily exceeded consensus estimates, with earnings per share (EPS) of $0.50 versus a projected $(0.31) loss and revenue well above the roughly $59.1 million forecast.
- For more detail on XNCR's Major News, Today's Price Move, Price Targets, and Forecasts, explore the linked pages.
- Explore Trending AI Robots to discover automated trading strategies and market signals.
Why the Quarter Matters for Xencor
XNCR's third quarter 2026 report marks a meaningful shift for the clinical-stage biotech, which has historically posted quarterly losses as it funds a pipeline of engineered antibody candidates. A surge in collaboration revenue—driven by royalty payments from Alexion and Incyte and milestone revenue from Astellas—pushed the company into profitability, a rarity for early-stage developers. In my view, investors are closely watching whether this revenue stream signals durable, non-dilutive funding that can reduce reliance on equity raises. The results also arrive against a backdrop of rising R&D investment, making the quarter a key test of XNCR's ability to convert partnered programs into steady income while advancing its own pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
XNCR reported third quarter 2026 revenue of $116.5 million, compared with $21.0 million a year earlier. The increase was primarily attributed to royalty revenue from Alexion and Incyte plus milestone revenue from Astellas.
On the bottom line, the company posted net income attributable to Xencor of $39.4 million, or $0.50 on a fully diluted per share basis, reversing a net loss of $6.0 million, or $(0.08) per share, in the third quarter of 2025.
Research and development (R&D) expenses rose to $84.3 million from $54.4 million, reflecting higher internal and external development costs, partially offset by lower stock-based compensation. General and administrative (G&A) expenses declined to $9.4 million from $14.2 million, driven by a non-recurring recovery of legal expenses. Other income, net, fell to $16.4 million from $41.5 million on lower unrealized gains from an equity security.
Reported EPS of $0.50 significantly outperformed the consensus estimate of a $(0.31) loss, and revenue of $116.5 million surpassed the roughly $59.1 million analyst forecast. Cash, cash equivalents, and marketable debt securities totaled $555.7 million as of September 30, 2026.
Market Reaction and Investor Sentiment
XNCR shares reacted positively to the results, rising modestly in after-hours trading following the release. The earnings beat—particularly the swing to a $0.50 per share profit against an expected loss—underscored investor enthusiasm for the company's growing royalty and milestone revenue base. Sentiment heading into the report had been constructive, with the stock up substantially over the trailing three- and twelve-month periods. The sharp revenue growth, driven by partnered programs rather than one-off items, appears to have reinforced confidence in XNCR's ability to generate non-dilutive cash flow. Key risk factors investors continue to weigh include the sustainability of royalty streams and rising R&D costs tied to the company's pipeline advancement.
Forward Outlook and Key Factors to Monitor
Looking ahead, XNCR reiterated its expectation to end 2026 with between $480 million and $500 million in cash, cash equivalents, and marketable debt securities, and to have sufficient resources to fund its R&D programs and operations into 2029.
Several factors merit attention. The Alexion settlement remains a meaningful cash source: XNCR received $52.5 million in August 2026 and is entitled to a final $52.5 million payment in the third quarter of 2027. Investors will also monitor the trajectory of royalty revenue from Alexion and Incyte, which drove much of the quarter's top-line strength.
Rising R&D expenses are likely to stay in focus as the company advances its pipeline, while any new milestone achievements from partners such as Astellas could add further revenue. The company's equity stake in Zenas—where obexelimab was licensed—represents an additional, potentially valuable asset. As always, clinical data readouts and regulatory progress will be central catalysts for a company whose long-term value depends heavily on development milestones. From what I see, this is important because it highlights how partnership-driven income can support ongoing innovation.
Using Tickeron’s AI Screener for Biotech Research
I often rely on Tickeron’s AI Screener when analyzing names like XNCR. The tool helps me filter peers by fundamentals, technical patterns, and AI signals, making it easier to put quarterly results into broader sector context without spending hours on manual screens. It has become a regular part of my process for spotting comparable opportunities in biotechnology.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XNCR in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 52 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 188 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 51 cases where XNCR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XNCR broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.527) is normal, around the industry mean (3.051). P/E Ratio (-14.185) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology
Advertisement